37115-47-2

Basic information

• Product Name: 2-(Methylamino)acetohydrazide
• Synonyms: 2-(Methylamino)acetohydrazide;2-methylaminoethanehydrazide
• CAS NO: 37115-47-2
• Molecular Formula: C₃H₉N₃O
• Molecular Weight: 103.12306
• Mol File: 37115-47-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(Methylamino)acetohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Methylamino)acetohydrazide(37115-47-2)
• EPA Substance Registry System: 2-(Methylamino)acetohydrazide(37115-47-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 37115-47-2(Hazardous Substances Data)

Usage

General Description

2-(Methylamino)acetohydrazide is a chemical compound with the molecular formula C4H10N2O and a molar mass of 102.135 g/mol. It is also known as Methylhydrazinecarboxamide and is used in the synthesis of various bioactive compounds and pharmaceuticals. It is a white to pale yellow crystalline powder with a melting point of 158-161°C. 2-(Methylamino)acetohydrazide is often utilized as a building block in the preparation of novel molecules for drug discovery and development. It is important to handle 2-(Methylamino)acetohydrazide with care and adhere to proper safety precautions when working with this chemical.

Upstream product

• 13200-60-7 Sarcosine ethyl ester 
• 5473-12-1 N-methylglycine methylester 
• 13515-93-0 N-methylglycine methyl ester hydrochloride 

Downstream Products

• 72606-31-6 C₁₄H₂₁N₃O 
• 72606-56-5 Methylamino-acetic acid [1-naphthalen-2-yl-meth-(Z)-ylidene]-hydrazide 
• 395106-20-4 ({3-[3-(4-Fluorophenyl)(1H-Indazol-5-Yl)](1H-1,2,4-Triazol-5-Yl)}Methyl)Methylamine 

Relevant articles and documents

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.